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Abstract
!
Prostate cancer (PCa) is the most common malignancy in men. Aggressive prostate
tumours must be identified, differentiated from indolent tumours, and treated to ensure
survival of the patient. Currently, clinicians use a combination of multi-parametric
magnetic resonance imaging (mpMRI) contrasts to improve PCa detection. While these
techniques provide very good spatial resolution, the specificity is often insufficient to
unequivocally identify malignant lesions.
Utilizing specialized MRI hardware developed for sensitive in-vivo detection of sodium,
this work has investigated differences in sodium concentration between healthy and
malignant prostate tissue. Patients with biopsy-proven PCa underwent conventional
mpMRI and sodium MRI followed by radical prostatectomy. Subsequent whole-mount
histopathology of the excised prostate was then contoured according to Gleason Grade, a
radiological assessment of tumour stage and aggressiveness for PCa. Tissue sodium
concentration (TSC) measured by sodium MRI was successfully co-registered with
standard image contrasts from multi-parametric MRI and also with pathologist confirmed
histopathology as the gold standard.
This proposed method provides quantitative, in-vivo sodium information from cancerous
human prostates. The results of this study establish the relationship between TSC and
malignant PCa, which could prove useful in initial characterization of the disease and for
active surveillance of indolent lesions. !
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Introduction

1.1 The Prostate Gland
The prostate is a walnut-sized organ whose primary function is to produce fluids
(prostatic fluid) associated with male reproduction. Prostatic fluid makes up 30% of
semen, by volume, with the remaining 70% made up of spermatozoa and seminal vesicle
fluid (1). The prostate is located directly below the urinary bladder and surrounds the
location where the prostatic urethra and the ejaculatory ducts merge. A small amount of
smooth muscle contained within the prostate aids with ejaculation, a secondary function
for the prostate (2).

Figure 1; Anatomy of the prostate gland. The peripheral zone (purple), central zone (red),
transition zone (blue), and the anterior fibromuscular stroma (green), as well as the
urethra (yellow) are shown.
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Four zones define the prostate gland (Figure 1): central, transitional, anterior
fibromuscular, and peripheral. The central zone (CZ) surrounds the ejaculatory ducts and
makes up roughly 20% of the prostate by volume. The transitional zone (TZ) surrounds
the proximal urethra and comprises 5% of prostatic volume. The peripheral zone (PZ)
comprises 70% of the prostate by volume and surrounds the CZ, TZ as well as the distal
urethra. Finally, the anterior fibromuscular zone (AFS) comprises 5% of the prostate and
is comprised of only fibrous and smooth muscle elements (3).

1.2 Prostate Cancer
1.2.1 Statistics
Prostate Cancer (PCa) is the most common malignancy for men in Canada, with one in
eight diagnosed overall. In 2014, there were 23,600 new cases of PCa in Canada alone
with 40% of men diagnosed between the ages of 60-69. Men who are diagnosed with PCa
have a relatively low probability (1 in 28) of death but also experience a diminished
quality of life (4). Most cases of PCa (99%) are adenocarcinoma, which is a defined as
neoplasia of epithelial tissue with glandular origin, glandular characteristics, or both (5).
Between 2001 and 2009, the mortality rate of PCa declined significantly, this is most
likely due to improved treatment options and/or the introduction of the prostate-specific
antigen (PSA) test but studies reported conflicting results (6,7).
1.2.2 Symptoms
Though early forms of PCa do not present symptoms, advanced stage symptoms range
from: prostatic bleeding, blood present in semen, bone pain, and urinary obstruction.
Patients could misinterpret lower urinary tract disease as urinary obstruction, which
occurs due to benign prostatic enlargement.
!
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1.2.3 Screening
According to the National Comprehensive Cancer Network (NCCN) practice guidelines,
asymptomatic PCa suspicions begin with an abnormal digital rectal exam (DRE). In this
process, a physician will palpate the prostate through the rectum to determine any
irregularities. Regardless of the outcome of other metrics, symptomatic patients receive a
bone scan to test for metastases. The NCCN also recommends the use of the PSA test,
which as many studies have concluded, is a controversial method (8).
Centres that use the PSA test as a risk evaluation tool (among other metrics) set a
threshold at which the patient should undergo biopsy. The level of antigen present in the
blood stream in order for a patient to undergo biopsy varies. While there is a correlation
between increasing risk of PCa and increasing PSA levels, there is no lower limit, which
eliminates the risk altogether (9). PSA thresholds set at 3 and 4 ng/ml had false positives
rates of 19.8% and 11.3%, respectively (10,11). The Prostate Cancer Prevention Trial
(PCPT) studied nearly 19,000 men between October 1993 and June 2003 in the United
States (12). The trial reported findings of PCa for 15% of men with a PSA < 4 ng/ml and
normal DRE, 30-35% of men with 4 ng/ml < PSA < 10 ng/ml, and 67% of men with a
PSA > 10 ng/ml (13,14).
Patients with positive PSA test results are scheduled for further screening techniques,
including prostate biopsy. Prostate biopsy is a procedure in which twelve core samples of
prostate tissue are systematically acquired by needle biopsy from the rectum. This
procedure is often aided by image-guided techniques such as ultrasound or magnetic
resonance imaging (MRI). Possible side effects of prostate biopsy include hematuria
(blood present in urine), infection, hospital admission, and in some cases death. An
!
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observational study of 1000 men who underwent prostate biopsy noted that patients had
experienced side effects such as: hematuria (31%), infection (0.9%), hospitalization
(2.1%), and death (0.2%) (15).
Overdiagnosis is a term used when disease is correctly detected but would not cause
noticeable symptoms or death and is an inevitable consequence of screening for disease.
The prevalence of overdiagnosis in PCa varies according to the frequency of screening,
threshold of the PSA test used, patient age, number of core samples taken, and disease
risk (16). It has been shown that 40-56% of men screened who received a diagnosis of
PCa can be attributed to overdiagnosis (15). While there has been a reduction in PCa
mortality from 38% in 1995 to 22% in 2006, quality of life has become a relevant
concern related to the problem of benefit versus harm.
1.2.4 Grading & Staging
Gleason Grading
Donald F. Gleason established the gold standard grading system for PCa in 1966.
Appropriately named the Gleason system; it has been amended twice in 1974 and 1977
by Gleason himself (17). The system is based upon low-power, microscopic observation
of morphological features of prostate tissue classified by Gleason. All tumours are judged
to fit within 5 categories, representing different states of complexity in morphology. A
tumour is graded depending on the most prevalent (primary) and the second most
prevalent (secondary) observed Gleason Grade. The combination of these two gradings is
called a Gleason Score (primary grade + secondary grade = Gleason Score) (18). Many
reports have confirmed the significance of Gleason Scoring and outcome after no
treatment (19), treatment with radical prostatectomy (20), and radiation therapy (21).
!
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Prostatic Intraepithelial Neoplasia (PIN) describes a lesion that, although isn’t cancerous,
could be a possible precursor to malignancy (9). PIN is most easily described as the
presence of prominent nuclei within an existing duct structure. The similarities between
PIN and prostatic carcinoma include: increased severity and incidence with age and
prominence within the PZ of the prostate (22). Benign Prostatic Hyperplasia (BPH) is the
formation of benign nodules within the prostate due to an increase in cell proliferation. In
some cases these nodules can obstruct the urethra, leading to painful urination (8).
A Gleason Grade of 1 (Figure 2(1)) describes tissue that is uniform, comprised of
separate, closely packed glands. Gleason Grades 1 and 2 are very well-differentiated and
in most cases today would be considered atypical adenomatous hyperplasia by
immunohistochemistry (18). Grades 1 and 2 patterns diagnosed from needle core biopsies
were given a higher grade at radical prostatectomy, and also had poor reproducibility;
therefore they are rarely assigned (23).

1!

2!

3!

4!

5!

Figure 2; Gleason Grades 1-5, where Gleason Grade 1 are least aggressive and Gleason
Grade 5 are most aggressive. With increasing Gleason Grade, prostate gland structures
are decreasingly differentiated. As Gleason Grade progresses, gland patterns shift from
well defined units to fused or poorly defined units with no internal lumina.
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Gleason Grade from biopsy is reliable and significant for Gleason Grade 3, which
represents the most common Gleason patterns reported from biopsy. In Grade 3, gland
units are typically smaller than Gleason patterns 1 and 2; infiltration between benign
glands is common (Figure 2(3)). In Gleason 3, gland units are still distinguishable with a
defined border, a distinction that separates Gleason 3 from Gleason 4.
In Gleason 4, a new tissue characteristic is introduced. Cribriform structures are
described as large irregular glands without recognizable lumina. Gleason 4 could also
present as fused, ill-defined glands with poorly formed glandular lumina (Figure 2(4)).
One consideration pathologists need to beware of is tangential sectioning, where the
biopsy needle’s trajectory is such that it bisects the glands at an angle that distorts the
appearance of the gland units. Tangential sectioning creates the impression of ill-defined
glands with inconspicuous lumina that could lead to a false-positive diagnosis as Gleason
4 (24).
The most aggressive pattern in the Gleason grading system is Gleason 5, where there is
no longer any glandular differentiation (Figure 2(5)). In pattern 5, the cribriform
structures from Gleason 4 are upgraded with central comedonecrosis. Comedonecrosis is
the presence of necrotic cells within the luminal space of the gland and/or karyorrhexis,
where the nucleus of a dying cell is distributed irregularly throughout the cytoplasm
(24,25).
The distinction between Gleason Grade 3 and 4 is an extremely important one. This is a
threshold that the NCCN (9) and Cancer Care Ontario (CCO) (26) has set to determine
which patients will undergo active surveillance (these patients will have routine follow-
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up examinations at set time intervals) and those patients who require immediate treatment
(these patients will undergo treatment procedures such as radical prostatectomy,
brachytherapy, and chemotherapy). By correctly distinguishing patients into therapy
groups, patients can be spared psychological and physical pain from unnecessary
treatment; as well as save an estimated $100 million in healthcare costs per annum in
Canada alone (27).
Staging
In order to deliver a clear diagnosis; clinicians use a staging system to distil all prognostic
factors into a single classification. The most commonly used staging system for prostate
cancer is the American Joint Committee on Cancer (AJCC) tumour, node, and metastasis
(TNM) system. Further subcategories of each classification are used to describe the
cancer in detail (8).
To describe the size and invasion of the tumour, “T classification” is used.
•
•
•
•

T1: the tumour is not apparent by DRE nor visible by imaging
T2: the tumour is confined to the prostate gland
T3: the tumour extends beyond the prostatic capsule
T4: the tumour is fixed or invades adjacent structures

To describe lymph node metastasis, “N classification” is used.
•
•
•

NX: lymph nodes were not assessed
N0: no regional lymph node metastasis
N1: metastasis present in regional lymph nodes

Finally, if the cancer has spread past the lymph nodes, “M classification” is used.
•
•

!

M0: no distant metastasis
M1: distant metastasis
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1.2.5 Cell Metabolism & Regulation
The regulation of intracellular pH is important for cellular function; it plays a role in cell
proliferation, invasiveness, drug resistance and apoptosis (28–30). Proliferative cancer
cells in solid tumours increase anaerobic glycolysis to compensate for hypoxia due to the
limited diffusion of oxygen across tissue (31,32). This increased anaerobic glycolysis
leads to a reduction of tumour pH through increased lactate production and hypoxic
adenosine triphosphate (ATP) hydrolysis. As a mechanism to prevent apoptosis, the cell
will increase proton efflux, regulating intracellular pH (33). One of the systems used by
cells to regulate pH is the Na+/H+ (NHE1) antiport, which is inherently coupled to the
transport of Na+ ions across cellular membranes (34–36). This antiport facilitates the
exchange of extracellular Na+ for intracellular H+. Its been shown that the NHE1
exchanger could also play a role in initiation of cell growth and proliferation (37,38). A
study by Rotin et al. demonstrated that human tumour cells lacking the NHE1 exchanger
either lost or severely reduced their ability to grow tumours (30). An upregulation of the
NHE1 antiporters is a mechanism used to cope with intracellular acidification, which in
turn increases intracellular sodium concentration (30,36,39,40). Expression of the NHE1
antiport has been observed to affect tumour cell migration through extracellular
acidification (41). Tumour cells metastasize through the metastatic cascade, in which the
cell migration step is dependent upon the degradation of the extracellular matrix through
acid extrusion (42). Based on solid tumours, increased intracellular sodium levels would
likely be expected as an inherent result of upregulated NHE1 (32). Cameron et al.
showed that “…rapidly dividing cells had significantly higher sodium concentration than
did the slowly dividing cells but significantly less sodium than did the tumor cells” (28).
Intracellular sodium concentration ([Na+]in) is largely regulated by a combination of
!
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NHE1 (influx) and Na+/K+ ATPase (efflux) and can vary by large amounts. Extracellular
sodium concentration ([Na+]ex) rarely deviates from plasma concentrations, which is
regulated by renal sodium exchange and tissue perfusion (28,39,40,43). Tissue Sodium
Concentration (TSC) is a weighted average of the [Na+]in and [Na+]ex based on relative
intracellular volume (IVF) and extracellular volume fractions (EVF). [Na+]ex is
essentially kept constant at ~140 mmol/L with sufficient tissue perfusion (44), while
normal [Na+]in is ~10-15 mmol/L (45–47). A study by Langer et al. showed that EVF
decreased from 68.8% to 52.1% while IVF increased in PCa when compared to normal
prostate tissue (48). Assuming a constant [Na+]ex, an IVF of 46.2% and an EVF of 52.1%,
[Na+]in can be calculated for a given TSC value. Intracellular sodium concentration is an
indirect measure of cell malignancy and mobility (28,41). Therefore a non-invasive
method capable of quantifying tissue sodium concentration could prove useful in
assessing cancerous tissue.

!
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1.3 Basics of MRI
Magnetic Resonance Imaging (MRI) is a diagnostic modality that is unrivalled in its
ability to produce excellent soft-tissue contrast images of biological systems high spatial
resolution and with no ionizing radiation (49). Developed in the early 1970s, the number
of clinical MRI units has grown to an estimated 25,000 with 266 systems installed in
Canada (50). To produce contrast, MRI exploits the interaction of nuclear spins within an
applied magnetic field. The most common nuclide utilized is the proton of the water
molecule because of its high abundance in the body (80 mol/L), intrinsic nuclear spin of
½ and large magnetic dipole moment. A fundamental physical property of nuclei, nuclear
spin is a combination of contributions from both unpaired protons and neutrons. Not all
nuclei are observable by MRI; only those that possess a non-zero-spin value. When
placed in a magnetic field, the magnetic dipole moments of non-zero-spin nuclei precess
around the magnetic field direction and will preferentially align, to a small degree, with
the magnetic axis. In the case of MRI, this axis exists along the bore of the magnet and,
by convention, is denoted by the letter z in a Cartesian axis system. This creates a small
net magnetization (M0) along the magnetic field direction. However, in the absence of a
dominant magnetic field, the angles of the precession of spins with respect to the z-axis
are randomly distributed resulting in no net magnetization. A particular nuclide precesses
at a specific frequency within a uniform magnetic field, termed the Larmor frequency
(ω0). The Larmor frequency of a nuclide is proportional to the strength of the field in
which it is placed (B0) and is given by
ω0 = 2πγB0

!
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where γ, the proportionality constant, is called the nuclear gyromagnetic ratio measured
in Hertz per Tesla. The gyromagnetic ratio is unique for each nuclide. Clinical MR
systems vary in magnetic field strength, measured in Tesla (T), from low-field (0.2T) to
high field (7T) systems. Most MRI scanners in operation today utilize a field strength of
1.5T but in recent years there has been a large increase in the number of higher field
strength magnets (3-7T) (50). Higher field strengths have the advantage of an increased
signal to noise ratio (SNR) for MRI associated with greater magnetization and higher
Larmor frequencies. This can allow for shorter imaging times at higher spatial resolution
but comes at the price of higher equipment costs, greater sensitivity to field
inhomogeneities, potential tissue heating and electromagnetic coupling between transmit
and receive structures (51).
An MRI produces signal by perturbing the bulk magnetization of tissue with radio
frequency (RF) waves at the Larmor processional frequency of protons. As the excited
magnetization relaxes back to equilibrium, it emits RF energy, which is also at the
Larmor frequency. The RF power is often applied by a dedicated transmit coil. This is a
tuned RF circuit, which is resonant at the Larmor frequency of the nuclide of interest. To
detect the relaxation of the magnetization, a separate proximal RF receive coil, resonant
at the same Larmor frequency can also be used for increased local signal sensitivity.
Excitation of the tissue magnetization is accomplished by short pulses of RF power
applied to the transmit coil. Before an RF pulse is applied the bulk magnetization is
oriented longitudinally aligned along the z-axis. A 90˚ RF pulse will flip the longitudinal
magnetization into the transverse (x-y plane) reducing the longitudinal magnetization to
essentially zero. The magnetization then relaxes back to the longitudinal equilibrium state
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through different mechanisms. Spin-spin (T2) and spin-lattice (T1) are the two
predominant relaxation features that affect the excited magnetization immediately
following an RF excitation pulse.
Spin-lattice relaxation represents the loss of energy from the spin system to the
surrounding lattice (environment). This exchange of energy is a result of local
fluctuations in the magnetic field due to interactions of tumbling molecules. Protons in
water molecules are tumbling in the environment of these fluctuating magnetic fields and
can gain or lose internal energy as a result of these electromagnetic fluctuations they
experience. For example, a larger number of magnetic fluctuations at or near the Larmor
frequency produce more effective spin-lattice relaxation. This exchange of energy
governs how quickly the tissue re-magnetizes after application of an RF excitation pulse
and how quickly repeated RF pulses can be applied. The longitudinal magnetization,
Mz(t), asymptotically relaxes back to the thermal equilibrium value as Mz(t) = M0(1-e-t/T1),
where the exponential time constant, T1, is the spin-lattice relaxation time governing this
process.
Spin-spin relaxation is due to the dephasing of the ensemble of spins from their coherent
precession after RF excitation to a nearly uniform distribution in the transverse plane.
This dephasing occurs due to slight differences in precessional frequencies for individual
spins arising from intrinsic magnetic field inhomogeneities. Apparent magnetic field
inhomogeneities experienced by nuclei in molecules are linked to the molecular size and
mobility of the molecules. Small, fast tumbling molecules, such as free water effectively
average out the magnetic field inhomogeneities, resulting in an apparently relatively
homogeneous local field, so that very little dephasing of the spins and longer T2 (spin!
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spin relaxation) times are observed. Nuclei in large, slow tumbling molecules such as fat
experience a relatively static magnetic field inhomogeneity, leading to more dephasing of
the transverse magnetization and faster signal decay (shorter T2 times) (49). The receive
RF coil detects an oscillating signal at the Larmor frequency with an exponentially
decaying amplitude whose exponential time constant is T2*, the effective spin-spin
relaxation time. T2* characterizes the apparent relaxation time due to the inherent sources
of magnetic field inhomogeneity mentioned above as well as external sources of
inhomogeneity due to imperfect magnetic field shimming and magnetic susceptibility
effects related to air/tissue interfaces and iron-containing blood. T2* is always shorter than
T2 .
T1

and T2 relaxation times are fundamental properties associated with a particular nuclide

for a given tissue and are observable as a bulk property. Knowledge of these relaxation
times are important for optimizing the imaging parameters of a pulse sequence to garner
the most signal from a particular sample or to optimize the image contrast between
healthy and cancerous tissue.
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1.4 Sodium MRI
1.4.1 Basics of Sodium MRI
As mentioned above, any nuclide that possess a non-zero spin value can, in principle, be
!

detected using MRI. Of particular interest are sodium (23Na) nuclei, which possess a !
spin value. 23Na MRI is technically difficult because of low sodium concentration in the
body (~90 mmol/L) verses the concentration of protons (80 mol/L), its low gyromagnetic
!

ratio (1/4 that of protons), and its ! spin. Sodium MRI is often referred to as

23

Na MRI

and despite its lack of success during early research (52), it has become more feasible in
recent years due to advancements in high-field MRI hardware, pulse sequence software,
and widespread implementation of multi-nuclear MRI systems (53–56).
1.4.2 Bi-Exponential Decay of Sodium
23

Na MRI is technically difficult due to the limited endogenous sodium concentration and

rapid spin-spin relaxation times; however, the very short T1 relaxation time supports
shorter repetition rates (TR), leading to faster signal acquisition and reduced imaging
times. Even with TR set to three times the T1 of 23Na (to allow for quantification of TSC
without T1 corrections), ten RF excitations are possible in one second. In addition to low
endogenous concentration,

23

!

Na MRI is challenging due to the intrinsic ! spin value of

sodium nuclei. This higher spin value, compared with that of the proton, results in biexponential T2 relaxation (two distinct components to the exponential signal decay) for
sodium (“long component”: 20-30ms and “fast component”: 1-2ms). Sodium nuclei can
!

! !

!

have four distinct energy levels (Zeeman energies) in a magnetic field, -!, -!, !, and ! and
can transition between each of them. A change between adjacent energy levels is called a

!
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single quantum transition, but changes between other levels are possible, double or triple
quantum transitions. Normally in an unrestricted watery solution containing sodium, all
transitions are single quantum, and have the same energy. In tissue, the movement of
sodium is more restricted - particularly within cells. This alters the relative amount of
short versus long component T2 decay, which is observed. For sodium imaging of tissue,
the long and short components comprise approximately 60% and 40% of the signal,
respectively. For quantification of TSC, a short acquisition delay (TE) is required to
observe both the short and long component T2 decay, which helps to reduce T2 losses
(52).
1.4.3 Separating Signal Components
Distinguishing between intracellular sodium and extracellular sodium is essential to the
success of 23Na MRI in biomedical research. Intracellular sodium reflects the stability of
the cellular membrane, as well as the state of cellular metabolism (57), while extracellular
sodium is usually fixed by perfusion. The triple quantum filtered (TQF) technique has
shown promise as an effective method of separating the signal from these two
compartments (58–60). TQF attempts to suppress the extracellular component of the
signal through manipulation of the bi-exponential decay due to the quantum transitions
between energy states. The TQF approach assumes that the long and short T2 components
of the signal are specific to the extracellular and intracellular compartments, respectively.
The experimental difficulty with TQF lies in the low SNR, which leads to longer scan
times and reduced resolution. There have also been reports of unwanted extracellular
sodium significantly contributing to TQF signals (58,61), therefore caution with this
technique is warranted. Bi-exponential weighted

!
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23

Na imaging is a promising technique

!

that utilizes both spin-density weighted and single-quantum-filtered imaging. It offers
compartment separation without the drawbacks of low SNR and longer scan times as in
TQF (62). The method uses a single-quantum-filtered image, which contains mainly
signal from mono-exponentially decaying sodium nuclei and a spin-density weighted
image, which contains signal from all sodium ions. The single-quantum-filtered image is
subtracted from the spin-density image to produce contrast mainly from the intracellular
compartment.
To obtain absolute sodium concentration information, calibration phantoms must be
employed. A large volume phantom of concentration 100-150 mmol/L is needed to assess
the RF coils, as well as two or more reference phantoms ranging in concentration from
20-150 mmol/L. The reference phantoms were integrated into the RF receive coil. These
phantoms both allow absolute sodium concentration measurements as well as provide
fiducial markers for registration purposes.
1.4.4

Disease Applications

Sodium MRI can detect changes in metabolism of tissue as well as cellular membrane
integrity. Healthy cells maintain a constant 23Na gradient across the cellular membrane. A
disruption of the cell membrane or impaired energy metabolism will result in an increase
of [Na+]in (57). Significant 23Na changes can be seen in myocardial infarction (63), stroke
(44), and cancer (64,65).

!

16!
!

!

Sodium levels have been shown to increase after stroke induced in rats as determined by
flame spectrometry of punch samples (66); these findings have since been confirmed with
23

Na MRI (67,68). Sodium MRI has also been shown as a possible tool to monitor

therapy that causes cell death such as chemotherapy. A xenograft animal model of PCa
(69) as well as breast cancer patients undergoing chemotherapy (70) reported a
significant decrease in TSC with a decrease in lesion size.
Imaging cancer with

23

Na MRI has been a growing area of research due to the

fluctuations of [23Na]in in cells with increased mobility and proliferation (30,36–40).
Sodium MRI studies have reported an increase in TSC of 50% in both brain and breast
cancers compared to normal tissue (64,65), and a doubling of TSC in low-grade glioma
(71). 23Na MRI has been employed to measure sodium in the healthy human prostate (72–
74) and the cancerous mouse prostate (75) but TSC values have yet to be measured in a
cancerous human prostate. The purpose of this thesis is to examine the potential for the
use of

23

Na MRI in the clinic as a non-invasive tool to aid clinicians in PCa treatment

stratification.!!
!
!
!
!
!
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Chapter 2
2

Hardware Construction and Testing

!
The!contents!of!this!chapter!were!previously!published!by!Farag!et#al.,!for!which!I!
was!second!author!(1).!

2.1 RF Hardware
To acquire signal from sodium nuclei two pieces of RF hardware were designed and built
in the 2nd Floor Imaging RF Engineering Laboratory at the Robarts Research Institute.
The first was a birdcage transmit-only coil (designed and built by Adam Farag (1)) with
an asymmetric cross section used to excite the sodium nuclei at their specific Larmor
frequency (Figure 3a).
To achieve this, the quasi-elliptical cross-section of an MR 750 GE 3T was determined
and a volume resonator large enough for a human torso was constructed for RF excitation
of the sodium magnetization. The top half of the resonator assembly is detachable from
the bottom to facilitate easy patient access. The resonator itself was constructed of 16
copper tubes functioning as rungs held in place by two Delrin® plastic end rings
machined to match the elliptical cross sections of the usable bore volume. The
asymmetric coil was tuned to resonate at the Larmor frequency of sodium nuclei at 3T
(33.78 MHz) according to values calculated in Farag et al. (1).
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Figure 3: a) The transmit-only asymmetrical birdcage coil. b) The Mark-3 endorectal
(ER) surface receive-only sodium coil. Both resonators were tuned to the Larmor
frequency of sodium at 3 Tesla (33.78 MHz).
The second piece of RF hardware designed and constructed was a rigid endorectal (ER)
surface coil to receive signal from the sodium nuclei at their specific Larmor frequency
(constructed by Adam Farag and myself (1)) (Figure 3b). A rigid design was chosen for
simplicity and to facilitate co-registration of

23

Na MRI and mpMRI imaging data.

Multiple versions of the probe were designed and constructed before the final design was
chosen. I coated all the probes with biocompatible sealant (MS151 MED, Masterbond,
NJ), which acted as a fluid-resistant seal as well as an additional layer of heat and
electrical insulation.
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The Mark-1a ER probe contained a dual-tuned RF loop for both 1H (127.74 MHz) and
23

Na (33.78 MHz) while the Mark-1b contained only a single tuned RF loop for

23

Na

imaging. Adam Farag manufactured the identical shells of the Mark-1a/b endorectal coils
from polycarbonate using 3D printing. The ER probe consisted of two separate volumes;
the proximal section inserted into the subject contained the RF circuit loop, while the
stem/base section housed the wires connecting the circuit with the balun and matching
circuitry in an adjoined external box. The Mark-1 probes had insufficient internal volume
within the proximal end to house reference calibration vials, which are essential for
absolute TSC measurement; therefore a larger Mark-2 version was constructed.
The single tuned (23Na-only) Mark-2 endorectal coil was 3D printed by Adam Farag from
ABS-M30 by Fotus® with all essential sections incorporated into one solid piece. The
proximal end housed the RF circuit loop as well as three-one-millilitre reference
calibration vials (which I constructed and implemented) containing 30, 90 and 150
mmol/L concentrations of NaCl in water. The stem section housed the wires connecting
the RF loop and the balun and matching circuits, which were contained within the distal
end of the probe. When inserted, the rigid, straight-stem design of the Mark-1 and -2 was
determined to interfere with the MR bed and affected the anatomy of the patient.
To resolve the interference of the probe and MR bed and improve patient comfort, a third
and final single tuned (23Na-only) probe was constructed (Mark-3). While the Mark-3 ER
coil contained identical RF circuitry to the Mark-2, the difference between the Mark-2
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and -3 was the incorporation of a 45˚ bend in the stem section and the ability to separate
the proximal/stem section from the distal section.

2.2 Imaging Phantoms
!

To test and calibrate the RF hardware, five phantoms were constructed:
1) a prostate-sized saline phantom of diameter 2.9 cm and NaCl concentration of
154 mmol/L, used for SNR and B1 measurements of the endorectal probes,
2) a hollow torso phantom of diameter 34.3 cm, used for loading the asymmetric
birdcage for B1 measurements,
3) a large cylindrical saline phantom of diameter 27.4 cm and NaCl
concentration 154 mmol/L, used for mapping the B1 field within the
asymmetric birdcage,
4) a small cylindrical saline phantom of diameter 15 cm, used for mapping the
3D sensitivity profile of the endorectal probes by submersion,
5) a body-tissue-equivalent homogenous phantom, used in specific absorption
rate (SAR) measurements of the endorectal probes.
Imaging parameters for all phantoms can be found in Farag et al. (1).
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2.3 Specific Absorption Rate Measurements
The specific absorption rate (SAR) surrounding the endorectal probes was measured to be
within acceptable levels, so not as to increase the temperature of surrounding tissue by
more than 1˚C (2). This was measured using a body-tissue-equivalent homogenous
phantom filled with hydroxyethyl cellulose (HEC) gel with electrical conductivity
matching that of human tissue (0.27 S/m). Six individual optically coupled temperature
transducers were placed on the probes, while two were inserted into the gel near the
probes. The temperature transducers had a precision of 0.1˚C and their values were
recorded at a frequency of 10 Hz for the duration of the imaging time.

2.4 Image Processing
The raw 23Na data were imported into Matlab (Mathworks, Natick, MA), where a k-space
Gaussian filter (34 × 34, SD: 9) was applied before Fourier transformation. All
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image sets of 10 NEX were registered together using the three reference calibration vials
as fiducials. The images were then averaged together to improve SNR; image sets with
significant motion during acquisition were discarded. The averaged in-vivo volumes were
then sensitivity corrected using a saline phantom volume, acquired with the

23

Na

endorectal coil submersed in the small cylindrical phantom with a diameter of 15 cm.
23

Na calibration data collected from this phantom used acquisition parameters identical to

those used for the in-vivo 23Na data collection. Calibration of the ER RF surface coil’s
receive profile was carried out using the method described in Axel et al. (3). To obtain
absolute TSC values from the

!
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Na data, the known sodium concentrations of the vials
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were plotted against average signal intensity values for the regions of interest (ROI)
corresponding to the internal calibration vials. The tissue sodium concentration was
calculated from
!"# = !

!!
!!!

!

(2.6.1)

where, ST and SPh were the signal within a voxel in the tissue and small, cylindrical,
saline phantom data, respectively. The quantity, U, is the slope acquired from the plot of
signal intensity versus sodium concentration. Eq 2.6.1 is adapted from Wetterling et al.
(4). The TSC uncertainty (ETSC) in each voxel was calculated according to Eq 2.6.2,
where SNRT and SNRPh are the SNR in each voxel of the tissue image and phantom
image, respectively. The parameter, δU, represents the uncertainty in determination of the
slope, U.
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Chapter 3
3

Manuscript For Submission to Radiology

!
Title: In-Vivo Sodium MRI of Prostate Cancer: Correlations with Gleason Grade
Using Whole Mount Pathology

3.1 Introduction
One in seven men will develop prostate cancer (PCa) in their lifetime and most of these
men will die with this disease, rather than as a result of it (1). Since the introduction of
the prostate specific antigen (PSA) screening test, there has been a concern regarding
overdiagnosis of clinically insignificant disease and therefore over-treatment (2–4).
Overdiagnosis has been shown to negatively affect the quality of life of patients as well
as being an economic burden on the healthcare systems (5). Diagnosis involves ranking
specific PCa lesions according to Gleason Grade, the gold standard scale from one to five
that is based on the differentiation of prostate gland units as scored by a pathologist on
routine hematoxylin and eosin (H&E) microscopy. The Gleason Score, a combination of
the primary and secondary grade present, is inherently related to tumor aggressiveness
and the strongest prognostic and predictive factor in the disease and therefore is an
essential assessment tool for guiding treatment plans (6–8). Urologists use transrectal
ultrasound-guided biopsy cores to estimate Gleason Score for patient-specific treatment
planning. Unfortunately, the biopsy only samples approximately 0.2% of the prostate and
carries an approximate 30-40% risk of under sampling clinically significant foci of
prostate cancer (9–11). The use of an alternative imaging-based method for estimation of
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tumor grade would be a significant benefit. Non-invasive identification of potentially
high-grade foci in the gland could be used to direct prostate biopsy or guide focal
treatment approaches. Early in the treatment pipeline, accurate determination of the
Gleason Score is essential to place patients in the proper treatment schemes according to
tumor grade (for example, active surveillance for men with low grade, low volume
lesions) in order to optimize patient outcomes and the use of health care resources.
Multi-parametric magnetic resonance imaging (MRI) is emerging as a method to improve
non-invasive PCa grading (12). Currently, clinicians use a combination of multiparametric MRI including T2-weighted, diffusion-weighted, and dynamic contrast
enhanced imaging to improve PCa detection (13,14). 1H contrast-enhanced imaging
exploits vascular volume and cellular organization changes through uptake of a
gadolinium contrast agent. While these techniques provide high spatial resolution, the
specificity is often insufficient to localize malignant lesions and assign a tumor grade. In
addition, current mpMRI interpretation relies on qualitative suspicion scores (PiRADS
scale), which are subject to inter-observer variation and require expert reading skills (15).
Thus an imaging test that could provide complimentary information about the location
and grade of intraprostatic cancer foci would be valuable.
Sodium (23Na) MRI has been shown to reveal important information about biochemical
and physiological processes within tissue. The tissue sodium concentration (TSC) in
normal tissue is a sensitive indicator of cellular integrity and energy metabolism (16–18).
TSC is a weighted average of the intracellular ([Na+]in) and extracellular sodium
concentrations ([Na+]ex), based on relative intracellular volume (IVF) and extracellular
volume fractions (EVF). [Na+]ex is essentially kept constant at ~140 mmol/L with
!
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sufficient tissue perfusion (19), while normal [Na+]in is ~10-15 mmol/L (20–22).
Therefore, the mechanisms in which TSC can vary are through extracellular volume
changes (cellular organization, density) or through changes in intracellular sodium
concentration (altered metabolism) (23,24).
23

Na MRI can be employed to obtain information about a combination of both

intracellular and extracellular changes within tissue. Increased activity of the sodiumproton (Na+/H+) antiport (25,26) and sodium-potassium (Na+/K+-ATPase) pump (17,27)
in cells have been linked to tumor malignancy. A study by Cameron et al. (1980)
concluded that slowly dividing cells had significantly lower [Na+]in than rapidly dividing
cells, while tumour cells showed significantly higher [Na+]in than both slow and fast
dividing cells (17). Previous studies have shown increased TSC in brain and breast cancer
measured by MRI (18,24). While in-vivo endogenous sodium imaging has been
demonstrated in both mouse (28) and human prostates (29,30), TSC has not been
measured in human prostate cancer. We have previously developed a transmit-only
receive-only (TORO) combination of an asymmetric birdcage coil and an endorectal coil
that provided sufficient sensitivity to image 23Na nuclei in the human prostate (31). The
purpose of the current study was to correlate in-vivo quantification of sodium with
Gleason Score in patients with PCa. In the work presented here, histologically identified
prostate cancer was registered to in-vivo human sodium imaging data using a previously
published and validated registration pipeline (32) that incorporates in-vivo 1H images
acquired during the same MR exam as well as ex-vivo 1H images of the prostate obtained
after prostatectomy. This study is the first to relate in-vivo MRI measured TSC of human
prostate cancer with histopathologically confirmed Gleason Score.
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3.2 Methods
!
3.2.1 Patients
Seven male patients (aged 61 ± 5) (Table 1) with biopsy-proven prostate cancer were
recruited between June 2013 and November 2014 in conjunction with a multi-modality,
image-guided prostate cancer study (IGPC-2) (32). In addition to the usual exclusion
criteria for MR studies (implanted devices etc.), men were excluded from this study if
they had prior therapy for PCa, use of 5-alpha reductase inhibitors (e.g. Finasteride or
Dutasteride) within 6 months of the study start, a prostate volume greater than 68 cc
(whole mount pathology limit), allergies to contrast agents and other administered agents,
insufficient renal function, and a residual bladder volume greater than 150 cc. Patients
were instructed to drink 30 mL of milk of magnesia the night before the MR exam and to
fast 12 hours prior to the exam.
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Category

Patient 1

Patient 2

Patient 3

65

64

53

14.96

5.05

4.22

Primary Pattern

3

3

3

Secondary Pattern

4

4

4

Overall Gleason Score

7

7

7

Prostate Volume (cc)

45

30

25

cT2c

cT2c

cT1c

76

64

92

eGFR (ml/min/1.73m )

95

116

79

Urea (mmol/L)

5.1

3.9

6.9

Residual Bladder Volume (mL)

78

224

165

Primary Pattern

3

3

3

Secondary Pattern

4

4

4

Tertiary Pattern

5

none

none

Overall Gleason Score

7

7

7

Pathological T-Stage

pt3b

pt3a

pt2c

Pathological N-Stage

pn0

pno

pn0

Pathological P-Stage

pmx

pmx

pmx

Age
Pre-Treatment Procedures
Pre-biopsy PSA (ng/mL)

Clinical T-Stage
Screening Bloodwork
Creatinine (µmol/L)
2

Post Radical Prostatectomy

Table 1: Clinically relevant information for three patients
who completed the study, including pre-treatment
procedures, screening bloodwork, and post radical
prostatectomy procedures.
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3.2.2 Sodium Imaging Exam Protocols
High-resolution T2-weighted (T2-w) cube images (TE: 162 ms, TR: 2000 ms, FOV: 140 ×
140 mm, voxel size: 0.44 × 0.73 × 1.4 mm, flip angle: 90˚) were acquired using a
standard inflatable 1H endorectal (ER) coil to allow for registration to histopathology.
23

Na imaging was performed using a custom-built ER receive-only RF coil and dedicated

asymmetric transmit-only birdcage RF coil described in Farag et al. (31). The
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Na

sequence was a broad-banded 3D efficient fast gradient recalled echo (bbefgre3D) with
the following parameters, TE: 1.5 ms, TR: 80 ms, FOV: 140 × 140 mm, voxel size: 4.4 ×
4.4 × 6 mm, and flip angle: 85˚. For registration purposes, a set of 1H axial, T2-w images
were acquired (TE: 139.2 ms, TR: 5300 ms, FOV: 140 × 140 mm, voxel size: 1.09 ×
1.09 × 3 mm, and flip angle of 90˚); the 1H axial T2-w images were taken with the 23Na
ER coil inserted to provide morphological context for the

23

Na images and to facilitate

co-registration with a master set of 3D T2-w images. For each patient, topical anesthetic
Xylocaine (2%) was applied before insertion of the ER coil. Three calibration vials
containing 30, 90, and 150 mmol/L of NaCl within the 23Na ER coil were used to scale
the sodium signal to absolute concentrations according to Farag et al. (31).

3.2.3 Ex-Vivo Imaging Exam
The prostate specimens were immobilized in a syringe of Christo-Lube MCG 1046
(Lubrication Technology, Franklin Furnace, Ohio), which is an MR-invisible fluorinated
lubricant that produces no MRI signal and also minimizes magnetic susceptibility
artifacts at the tissue-prostate boundary. Excised prostates were prepared (described
below) and imaged with both T1-weighted (T1-w) (TE: 2.34 ms, TR: 6.41, FOV: 140 ×
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140 mm, voxel size: 0.73 × 0.55 × 0.6 mm, flip angle: 15˚) and T2-w (TE: 114 ms, TR:
2000 ms, FOV: 140 × 140 mm, voxel size: 0.73 × 0.44 × 0.6 mm, flip angle = 90˚)
imaging contrasts using a 6-channel 1H carotid coil. These images assisted in accurate
registration to histopathologic registration.
3.2.4 Whole-Mount Histopathology
Following radical prostatectomy specimens were marked with cotton threads soaked with
a blue tissue dye doped with gadolinium. Three threads were pierced through the prostate,
and seven threads were fixed to the surface to serve as fiducial markers, prior to ex-vivo
MRI. The prostate midglands were sliced into ~4-mm transverse sections before paraffin
embedding, leaving enough of the apex and base to be sagitally sliced for routine
pathology analysis. Using a microtome, a 4-µm slice was obtained from each section and
stained with H&E. The slides were then scanned at high resolution (0.5-µm isotropic
resolution, 24-bit colour) using a bright-field slide scanner (ScanScope GL; Aperio
Technologies, Vista, California) and subsequently contoured (Gleason Grading) and
confirmed by a pathologist (32). Cathie Crukely, Dr. Mena Gaed and Dr. Jose GomezLemus contributed to histopathology.

3.2.5 Registration
Co-registration of image data was necessary due to the deformation of tissue, caused by
differing geometries of the ER probes and the uncompressed nature of the tissue ex-vivo.
Comparison of contoured histopathology and

23

Na MRI data was achieved through a

complex registration pipeline, involving several image contrasts. The registration pipeline
is an important and unique part of this research study. Figure 4 outlines all image
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contrasts used and their position in the pipeline. All registration was completed using 3D
Slicer (Surgical Planning Laboratory, Harvard Medical School, Boston, Massachusetts),
with a non-rigid, interactive, thin-plate spline (TPS) extension by Gibson, E. (2014) (33).
Approximately 40 fiducial points were identified in pairs between two imaging volumes
that were to be co-registered. Fiducials were placed on physiologically relevant ROIs, as
well as patient-unique ROIs such as benign hyperplasia nodules and cystic spaces. In
each registration, a reference volume and an input volume was chosen; where the
reference volume remained unchanged and the input volume deformed according to the
fiducial points.

a)

b)

c)

d)

e)

f)

Figure 4: The registration pipeline for all imaging data involved in the study. The 23Na
volume, a) and body coil in-vivo T2-weighted volume, b) are registered to the endorectal
in-vivo T2-weighted volume, c). The contoured histopathology, d) and the ex-vivo T1- and
T2-weighted volumes (panels e) and f), respectively) are also registered to the endorectal
in-vivo T2-weighted volume.
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3.2.6 Statistical Analysis
Once each

23

Na MRI volume had been registered to corresponding histopathology, the

pathologic contours on each slice were separated according to peripheral zone (PZ) and
central/transitional zone (CTZ) as well as Gleason Score. In 3D Slicer, pathologic
contours were imported as a separate mask from the remaining normal tissue and
converted to scalar (gray scale) images. Each pathologic Gleason Score possessed its own
unique intensity value, which were separated using a combined thresholding/ROI
approach. This approach consisted of an initial manual selection of the bulk lesion,
followed by an automated selection of the remaining pixels according to the desired pixel
intensities. Within each histopathology image, Gleason Scores were separated into PZ
and CTZ categories by manual segmentation on T2-w images. The anterior fibromuscular
zone was not analyzed separately due to low

23

Na signal and an inability to distinguish

the zone on mpMRI. The remaining tissue in the histopathology images was designated
‘normal tissue’ according to zone. The label maps were overlaid on the registered

23

Na

images and the overlapping TSC values within the contours of the lesions were recorded.
All data were imported into GraphPad Prism (v6.0f, GraphPad Software, San Diego,
California) and subsequently analyzed using a one-way ANOVA (Tukey test) to assess
significance between grades.

!

40!

3.3 Results
Of the initial seven patients scanned with 23Na MRI, 3 were included in the analyses. In
the remaining four patients; two were scanned with an ER coil that did not include
reference standards (TSC could not be calculated); one patient did not return for radical
prostatectomy surgery so histopathologic information was not available; and data from
the fourth patient was excluded due to uncorrectable motion during image acquisition.
Clinically relevant patient information is provided in (Table 1). Six different Gleason
Grade groups were observed (Figure 6), according to the primary and secondary features
present.

TSC)(mmol/L)
200

Central,)Transitional)
Zones

TSC)Uncertainty)(%)
35

!
!

Peripheral)Zone

140

20

0

0

Calibration)Vials

Figure 5: A representative, unregistered, coloured map of the tissue sodium concentration
(TSC) in one slice with its corresponding measurement uncertainty in percentage. Central
and transitional zones are combined, with the peripheral zone outlined separately.
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Non-rigid registration of the

23

Na MR images to the contoured histopathology was

accomplished to an accuracy of ~2 mm. The average TSC in normal peripheral zone
tissue in all patients was measured to be 74.6 ± 6.7 mM (Figure 5). There was a
statistically significant difference in TSC (Figure 6) between highly aggressive lesions (≥
Gleason 4+3) and moderately aggressive lesions (≤ Gleason 3+4) for Patients 1 and 2
(p<0.0001); there were no Gleason 4+3 lesions present in Patient 3. The TSC between all
Gleason Scores were significantly different (p<0.0005), with the exception of PIN vs.
Gleason 4+3 in Patient 1 (p=0.3776), and PIN vs. Gleason 3 in Patient 2 (p=0.9892).

!

42!

*

NS

*

!

NS

*

!

!

*

*
*

!
!

!

!
Figure 6: Three patients with biopsy proven prostate cancer underwent 23Na MRI to
determine the TSC in different grades of tumour tissue. The bottom right panel shows a
representative histopathology slice from one patient. All Gleason Grade groups are
significantly different from each other (p<0.05) with the exception of PIN and Gleason
4+3 in Patient 1 and PIN and Gleason 3 in Patient 2. Red bars highlight the threshold
between active surveillance and active treatment (Gleason 3+4/Gleason 4+3). Error bars
represent one standard deviation for all voxels of that Gleason Score.
!
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3.4 Discussion & Conclusion
We report the first in-vivo

23

Na MR measurements from a cancerous human prostate.

TSC levels were significantly increased in lesions with a high Gleason Score when
compared to a low Gleason Score, and that of normal tissue within respective zones.
Previously, we have demonstrated that TSC can be consistently measured with high
signal-to-noise ratio (SNR) over the entire prostate (31).
Dividing Gleason Score into qualitative low- (Gleason Score ≤ 3+4), and high-risk
(Gleason Score ≥ 4+3) subgroups that correspond with treatment groups would establish
the potential use for 23Na MRI in prostate cancer diagnosis. Patients who fall into the low
category should be monitored under the active surveillance branch in the National
Comprehensive Cancer Network’s (NCCN) guidelines (34). Patients in the high-risk
category should undergo immediate treatment options within the NCCN’s guidelines.
While Cancer Care Ontario (CCO) maintains that patients with a Gleason Score of 7
should undergo active treatment, with the exception of select patients with low volume
Gleason 3+4 PCa (8). More reliable noninvasive identification of biologically significant
foci in the gland may enable targeted biopsy, focal therapy or focal dose escalation
strategies (35–39).
This study involved the development and application of advanced MRI hardware and
imaging data analysis including high-resolution whole-mount digital histopathology, and
the ability to register it in 3D to MRI data to a high degree of accuracy (~2 mm). The
histopathology alone required an average of 70 hours of time per prostate from an
experienced pathologist. The registration pipeline incorporated a novel automated
registration technique with sub-millimeter accuracy (40) as well as a manual, interactive
!
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TPS technique (32), both capable of 3D, whole-volume registration. Accurate registration
and detailed histopathology is essential in determining that the TSC measured in a
specific ROI is in fact a cancerous lesion as determined by gold-standard histopathology
(Figure 7). Finally, the development of sensitive integrated TORO RF hardware for
sodium imaging was a key enabler for this research (31).
*

d

e

a

c

Figure 7: (a) high-resolution T2-weighted 1H Cube image, (b) an axially acquired 1H T2weighted image, (c) and the distribution of endogenous sodium concentration (d-f) with
corresponding histology contours overlaid of an oblique slice through a prostate with
biopsy-proven cancer. Grey contours represent prostatic intraepithelial neoplasia (PIN, a
possible precursor to cancer); blue and red outlines are Gleason 3 and Gleason 3+4
lesions, respectively.
The current study shows that TSC increases with increasing Gleason Score in patients
with prostate cancer. While we are unable to associate this correlation with specific
cellular changes, it is likely due to cellular reorganization (volume changes) and
increased intracellular sodium concentration (24). With increasing Gleason Score,
cellular density increases, which leads to a decreased extracellular volume. The
!
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extracellular matrix, if in constant exchange with the vasculature, maintains a sodium
concentration of ~140 mM (41), while the intracellular sodium concentration in normal
prostate tissue is on the order of ~10-15 mM (18). Assuming a constant [Na+]ex, a
cancerous IVF and EVF of 46.2% and 52.1%, respectively, and a normal IVF and EVF of
31.2% and 68.8%, respectively; [Na+]in can be calculated for a given TSC value (42). The
average TSC increase across all patients from normal tissue to Gleason 3+4 was ~11 mM
(16%); therefore the [Na+]in can be estimated to increase from 23.3 mM to 39.5 mM.
Cancer cells have been shown to exhibit an increased metabolism, which supplies the cell
with enough energy to support accelerated proliferation and enhanced motility (43). The
caveats of this increased metabolism include an upregulation of the sodium-proton
(Na+/H+) antiport (25,26) and an inhibited sodium-potassium (Na+/K+-ATPase) pump
(17,27). As the tumor cell favors anaerobic glycolysis, the proton concentration within
the cell increases reducing pH. Na+/H+ antiport is the major mechanism used to reduce
the concentration of intracellular protons (16). As protons are pumped out decreasing the
intracellular pH, the intracellular sodium concentration consequently increases. An acidic
extracellular environment is also favored by the cancer cells, as it aids in cell motility
(44) and invasiveness (45). The increased [Na+]in is not directly distinguishable from
[Na+]ex but with assumptions of a constant [Na+]ex (19); and intracellular and extracellular
volume fractions from PCa tissue (42) it is possible to indirectly estimate [Na+]in from
TSC.
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A limitation of the TSC measurement method is the inability to directly differentiate
intracellular and extracellular sodium signal. As a result, we are unable to precisely
measure the intracellular sodium concentration without knowing the relative
compartment sizes within the tissue (assuming a known extracellular concentration). In
principle, triple quantum filtering (TQF) could be used to discriminate signal from only
the bound sodium ions but bound sodium is not exclusively found in the intracellular
compartment (46,47). TQF techniques also have limited SNR and high sensitivity to B0and B1-inhomogeneities making it a technically difficult prospect (48). One limitation of
this study is the small sample size, which limits the ability to make predictions about the
general population.
Due to the limited sodium concentration in tissue, the spatial resolution of sodium MRI is
modest compared to proton imaging (~5 mm3 vs. ~0.5 mm3). The pulse sequence used in
this study was a bbefgre3D sequence that traversed k-space according to a Cartesian
trajectory. 3D-Spiral pulse sequences, which are optimized for fast T2 relaxation and
efficient coverage of k-space, could prove promising in increasing SNR. Further
development in this area could potentially increase spatial resolution and/or reduce
acquisition times.
The inherent limitation of a surface ER coil is the receive profile, in which the signal
requires sensitivity correction; due to the inhomogeneous receive profile. This issue is
apparent not only in 23Na MRI but present in all prostate MRI (including 1H MR), where
high-resolution imaging requires the use of an ER coil.
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23

Na MRI is not specific to cancerous lesions, that is, regions of low signal intensity (or

TSC) are not necessarily regions of normal tissue and regions of high signal intensity are
not necessarily cancerous lesions.

23

Na MRI could prove to be a valuable addition to

mpMRI to characterize lesions but at this point is not specific enough to detect lesion and
lesion boundaries, which could explain the variation of TSC with increasing Gleason
Score.
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Chapter 4
!

4

Discussion & Future Work

4.1 Discussion
!
4.1.1

Overview

Sodium MRI is a non-proton (x-nucleus) contrast-agent-free imaging technique deriving
image contrast from the density of endogenous

23

Na ions in tissue. Using

23

Na MRI, it

was possible to quantify tissue sodium concentration in-vivo, which has been shown to be
an indicator of cellular metabolism and membrane integrity (1). Two custom-built RF
coils; an asymmetric transmit birdcage coil, and an ER receive coil, allowed for
acquisition of MR signal from the 23Na nuclei. The TPS registration made it possible to
compare gold-standard, whole-mount histopathology grading of PCa with the sodium
contrast with a registration accuracy of a few millimetres. Using 23Na MRI, the first inman quantification of sodium levels in the cancerous prostate was reported here.
4.1.2

Clarification

All in-vivo sodium contrast derived in this study was from endogenous

23

Na nuclei. No

introduction of sodium by oral or intravenous routes or any other contrast agent was
required. As a result, the imaging period was not limited by agent wash-in/washout
kinetics, nor was any approval required for contrast agent administration.
The data analysis was categorized into PZ and CTZ to account for the differences in
biologic functions, genetics, and prognoses between zones (2–4). Due to these
differences, generalizations cannot be made about the whole prostate, only within zones.
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It should also be noted that T2-w contrast alone is non-specific to PCa in the PZ and can
also result from other low-intensity lesions such as scarring, hyperplasia, and prostatitis
(5). PCa mpMRI exams may benefit from a complementary contrast such as 23Na MRI,
which is specific to PCa.
4.1.3

Clinical Significance

At this juncture, we have been able to image, quantify and accurately co-register TSC
with histopathological findings for three men with PCa. All three of these cases showed a
significant positive trend of increased TSC with Gleason Score. This finding is in
agreement with the literature of both brain and breast cancers, where there was an
increase in observed TSC in malignant tissue when compared to normal contralateral
tissue (6,7). As shown in Figure 6, normal PZ tissue had a lower TSC, when compared
with the progressively aggressive scores of PIN, Gleason 3, Gleason 3+4, Gleason 3+5,
Gleason 4+3, and Gleason 4. Of further importance, was the significance between lesions
with Gleason Score 3+4 and Gleason Score 4+3 (Figure 6). According to the NCCN and
CCO, this threshold is of critical value; any patient with a Score of 3+4 or less (≤ 3+4)
should be placed in active surveillance, while patients with a Score of 4+3 or greater (≥
4+3) should undergo immediate treatment (8,9).
A recent review of low-risk PCa in Canada concluded that the heath care system could
save as much as $100 million annually by correctly stratifying PCa patients in
appropriate treatment schemes (10). The savings were attributed to avoiding treatment in
patients who died from causes other than PCa (treatment not required) and patients still
receiving active surveillance. Not only would proper treatment planning alleviate the
economic burden of overdiagnosis, the benefits are also apparent in the quality of life of
!
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patients. Even taking into consideration the clinical discomfort of treatment as well as the
psychological burden of active surveillance, a patient’s quality-adjusted life expectancy
(QALE) is higher in patients who undergo active surveillance (QALE = 11.07) when
compared to brachytherapy (QALE = 10.57), intensity-modulated radiotherapy (QALE =
10.51), and radical prostatectomy (QALE = 10.23) (11).
A practical limitation of 23Na MRI at this time is the requirement of a multinuclear MR
scanner with the corresponding specialized hardware. While not every MRI system is
capable of detecting nuclei other than protons, existing systems could be upgraded for
this capability. Multinuclear MRI systems are also becoming more common in hospitals
in recent years (12).

4.2 Future Work
4.2.1

Twisted Projection Imaging

Twisted Projection Imaging (TPI) has the benefit of reducing the number of excitations
(NEX) needed for a complete 3D image, therefore reducing the overall scan time. When
acquiring signal in the frequency domain (k-space) TPI uses a series of spiral gradient
trajectories, programed onto corresponding cones of differing angles that cover one
hemisphere of k-space. This technique allows for more efficient sampling of the higher
frequencies that are responsible for image detail, while preserving the lower spatial
frequencies that are responsible for general shape and overall image contrast (13). TPI
has been used successfully in assessment of stroke (14), cardiac tissue (15), and brain
cancer (6). Implementing TPI imaging for

23

Na MRI could substantially increase SNR

affording reduced imaging scan (~10 min.) and/or increased resolution for this contrast.
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4.2.2

RF Hardware Improvements

The current study utilized an ER probe to receive sodium signal from the prostate and
surrounding tissues, which led to the need for sensitivity correction of data for
homogenous coverage over the prostate. The ER probe contains a single loop surface
coil, resonating at the Larmor frequency of 23Na nuclei at 3T. An inhomogeneous receive
profile whose sensitivity drops off rapidly with distance from the coil loop is an inherent
property of a surface coil. An external

23

Na tuned, non-rigid RF receive array coil,

integrated with the existing transmit RF hardware would have the potential to produce a
more homogeneous sodium contrast over the entire prostate. The array coil would be
placed directly onto the pelvis of the patient to increase the penetration depth of imaging.
Unfortunately, non-rigid array coils are subject to geometrical changes with patient
anatomy and may require RF tuning on a per-patient basis, particularly due to the low
gyromagnetic ratio of the 23Na nucleus. Evaluation of the receive sensitivity for such an
arrangement would also require further investigation.
The single-tuned nature of the

23

Na ER probe required the sequential insertion of two

probes (23Na and 1H), which is uncomfortable for the patient, and a time-consuming
intermediary step. The use of a dual-tuned

23

Na/1H ER probe would shorten total exam

time and improve the overall patient experience. As mentioned above (3.2), a dual-tuned
ER probe was initially developed, which was resonant at both sodium (23Na) and proton
(1H) frequencies but its sensitivity at the sodium frequency was inferior to a sodium-only
ER RF coil. Therefore, the dual-tuned ER coil was not used for this preliminary study;
however, in future work, the advantages of such a coil may out-weigh the SNR penalty
when one considers its benefits for image registration and patient comfort.
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4.2.3 Additional MRI Contrast Comparisons
This research has established that the integrated transmit-only, receive-only RF hardware
developed by Farag et al. (16), is capable of accurately determining sodium levels in
prostate cancer. More importantly, these measurements of TSC in prostate lesions have
been directly compared with Gleason Score through a unique image registration pipeline.
This pipeline can also be used to investigate the correlation of other mpMRI contrasts
(T2-w, DCE, and ADC) with Gleason grading and compare it with these sodium results.
Currently there are no comparisons of T2-w and ADC image contrasts with the gold
standard of pathology. If 23Na MRI provided a significant advantage over current mpMRI
contrast mechanisms in grading PCa, its utility within the clinic could be highlighted. The
ability to distinguish between patients who should be placed in active surveillance and
those who require immediate treatment shows great potential but requires further
investigation.

4.3 Conclusion
This study highlighted the efficacy of in-vivo sodium magnetic resonance imaging for
human prostate cancer. This thesis expanded on the work of Farag et al. (16) utilizing a
23

Na-tuned TORO RF coil system to image the prostate and translated the pre-clinical

research of Bartha et al. (17) to non-invasively assess tissue sodium concentration in
human prostate cancer. The purpose of this thesis was to examine the potential for the use
of

23

Na MRI in the clinic as a non-invasive tool to aid clinicians in PCa treatment

stratification.! The sodium RF hardware was used to acquire quantitative endogenous
sodium information, which is an indirect measure of cellular metabolism and integrity.
The sodium contrast was registered to gold-standard Gleason Scores determined from
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whole-mount histology, following radical prostatectomy. Analysis of these imaging data
revealed a significant increase in TSC with increasing Gleason Score, as well as a
significant difference between Gleason Scores 3+4 and 4+3. This distinction is of great
importance because it is the threshold for defining treatment in the clinic. Prostate
cancers with scores ≤ 3+4 are typically classified for active surveillance while scores ≥
4+3 are identified for immediate treatment. With further research, sodium MRI has the
potential to become a complementary mpMRI contrast for non-invasive grading and
active surveillance of this disease.
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Appendix A – Supplementary Methods
Multiparametric Proton MRI Protocol
Patients were instructed to fast 12 hours prior to the exam, as well as drink 30 mL of milk
of magnesia the night before. Upon arrival, patients were subjected to a screening exam
to ensure all exclusion criteria had been followed. After screening, patients were escorted
to the scanner bed, where all imaging took place. Calibration scans were acquired before
introducing the 1H endorectal probe to locate the prostate. Xylocaine (2%) was applied as
a topical anaesthetic before the insertion of the probe. After the 1H probe was introduced,
two diffusion-weighted imaging (DWI) sequences were acquired with b-values of 100
and 800 s·mm-2 to calculate an apparent diffusion coefficient (ADC) map; followed by a
T2-weighted (T2-w) Cube ‘Master’ sequence; and a dynamic contrast-enhanced (DCE) 3D
sequence. Imaging parameters from the three sequences can be found in Table 2.5.1.
Following the mpMRI exam the 1H probe was removed and the patient was given a tenminute break before the sodium examination.
Imaging Contrast
Method

TE/TR
(ms)

FOV
(mm)

Voxel Size
(mm)

Flip
Angle

Bandwidth
(KHz)

Apparent Diffusion
Coefficient MRI

68.1/5600

140×140

1.1×0.55×3.6

90°

250

Dynamic ContrastEnhanced MRI

1.54/3.1

100×140

0.78×1.1×3

12°

83.3

T2-Weighted MRI

162/2000

140×140

0.44×0.73×1.4

90°

31.2

Table A: Imaging parameters (TE/TR, FOV, Voxel Size, Flip Angle, and Bandwidth) of
ADC, DCE and T2-w contrasts acquired in the mpMRI session.
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Detailed Registration Steps
2.7.1

Step 1

The initial registration step in the pipeline (Figure 3.2.5.1a-b) involved a rigid
registration between the

23

Na volume and the 1H Axial T2-w volume, acquired serially.

This registration step was necessary to correct for any motion that may have occurred
between

23

Na and 1H sequences. Fiducial points were fixed to the three reference

calibration vials before a simple rotation/translation matrix was applied.
2.7.2

Step 2

The second step in the pipeline (Figure 3.2.5.1b-c) was the first non-rigid registration
necessary due to the differing geometry between the

23

Na and 1H endorectal probes.

Fiducial points were identified in pairs on both the 1H axial T2-w volume and the 1H
Master T2-w volume on ROIs, as described above.
2.7.3

Step 3

The third step in the pipeline (Figure 3.2.5.1f-c) utilized the non-rigid registration
because of the deformation of tissue after radical prostatectomy. In this registration, the
ex-vivo T2-w volume was the input image data that were deformed to the 1H Master T2-w
reference.
2.7.4

Step 4

The fourth step (Figure 3.2.5.1e-f) did not require any registration techniques because
both volumes involved (ex-vivo T1-w and ex-vivo T2-w), were acquired in the same
imaging session without movement of the sample.
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2.7.5

Step 5

The fifth and final step (Figure 3.2.5.1d-e) registered the individual, digital whole mount
histopathology images to the ex-vivo T1-w volume with sub-millimeter accuracy (18) by
optimizing an affine transformation to minimize the fiducial registration error between
the superficial and internal fiducial strands on MRI and the cross-sections of the fiducial
strands on histology. Next, the TPS transformation was interactively defined to
compensate for deformation between the ex-vivo and in-vivo MR images.
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Appendix B – Hardware Approval
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Appendix C – Human Participant Approval
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Appendix D – Data Collection Form
Protocol IGPC-2

Patient Initials: ___ ___ ___ Study #: IGPC2-0 __ __

Multi-modality Prostate Cancer Image Guided Interventions
CASE REPORT FORM

Patient’s  DOB:  _______/_____/_____ (YYYY-MM-DD)
Cohort:

□ Cohort 1 -Radical Prostatectomy

□ Cohort 2 -Prostate Biopsy

Main Study Informed Consent

□ Patient has read LOI
□ Patient states understanding and all questions answered to their satisfaction
□ Informed consent obtained, Date: _______/_____/_____
□ Patient received copy of consent form
Optional PET/MRI Imaging Informed Consent
Did the patient agree to optional PET/MRI Imaging

□  No □  Yes

If yes:
Date informed consent obtained: _______/_____/_____
Consent version date: _______/_____/_____

Optional Na MRI Imaging Informed Consent
Did the patient agree to optional Na MRI Imaging

□  No □  Yes

If yes:
Date informed consent obtained: _______/_____/_____
Consent version date: _______/_____/_____

Page 1 of 9
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Protocol IGPC-2

Patient Initials: ___ ___ ___ Study #: IGPC2-0 __ __

Multi-modality Prostate Cancer Image Guided Interventions
CASE REPORT FORM

Limited Medical History
Yes

No*

Allergic reaction to Lidocaine gel (topical analgesic)
Allergic reaction to Buscopan (anticholinergic/ system antispasmodic)
Allergic reaction to Magnevist (contrast agent for MRI)
Allergic reaction to iodine contrast (contrast agent for Dynamic CT)
Allergic reaction to 18F-Choline (radio-isotope for PET scan)
Contraindications to Buscopan such as myasthenia gravis, untreated
narrow angle glaucoma, prostatic hypertrophy with urinary retention,
stenotic lesions of the gastrointestinal tract, tachycardia, angina,
cardiac failure or megacolon
Contraindications to MRI such as pacemaker or other electronic
implants, known metal in the orbit, cerebral aneurysm clips or
claustrophobia.
*All answers must be 'no' to maintain eligibility.

Imaging Requisitions:
PET/ CT Nuclear Medicine Requisition completed with patient
X-Ray Contrast Injection Patient Questionnaire
Robarts MRI Research Consent Form completed with patient
*Please enter Robarts MRI Consent and X-ray Contrast Questionnaire into database.

Patient instructed on MRI Prep:
30 mL of milk of magnesia night before
NPO prior to exam by 12 hours
Patient instructed on PET/CT Prep:
Clear fluids only and nothing to eat 4 hours prior
250 mL water 30 minutes prior to exam

Date Completed with patient: _____/_____/_____ (cannot be before consent date)
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Protocol IGPC-2

Patient Initials: ___ ___ ___ Study #: IGPC2-0 __ __

Multi-modality Prostate Cancer Image Guided Interventions
CASE REPORT FORM

Eligibility Criteria
Inclusion Criteria
Provision of informed consent for this study.
Male, aged 18 years or older.
Pathologically confirmed prostate cancer on previous biopsy.
Suitable for and consenting to radical prostatectomy for treatment of
prostate cancer, or repeat biopsy as standard of care.
Exclusion Criteria
Prior therapy for prostate cancer (including hormone therapy), with the
exception of radiation therapy for Cohort 2 only.
Use of 5-alpha reductase inhibitors, i.e. finasteride (Proscar) or
dutasteride (Avodart) within 6 months of study start. Patients
undergoing a 6-month washout period prior to study start will be eligible.
Inability to comply with the pre-operative imaging panel.
Patients scheduled for radical prostatectomy with prostate size
exceeding dimensions for whole mount pathology slides.
Allergy to contrast agents to be used as part of the imaging panel.
Sickle cell disease or other anemias.
Insufficient renal function (eGFR <60 ml/min/1.73m2).
Residual bladder volume >150 cc (determined by post-void ultrasound).
Hip prosthesis, vascular grafting or sources of artifact within the pelvis.
Contraindication to MRI:
o Pacemaker or other electronic implants
o Known metal in the orbit
o Cerebral aneurysm clips

Yes

No*

Yes*

No

*If any checkmarks appear in this column patient is ineligible.

Is patient eligible to continue?

Yes

No

Date of Eligibility Assessment: _____/_____/_____
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Patient Initials: ___ ___ ___ Study #: IGPC2-0 __ __

Protocol IGPC-2

Multi-modality Prostate Cancer Image Guided Interventions
CASE REPORT FORM

Pre-Treatment Procedures
Physical Exam including DRE
Pre-biopsy PSA

Date: _____/_____/_____

______ ng/mL Date: _____/_____/_____

Date of Diagnostic TRUS Biopsy Date: _____/_____/____ (confirming prostate cancer)
Prostate Volume (from TRUS Biopsy):

______ cc

Clinical Staging:

cT1a

cT1b

cT1c

Pathological Staging:

pT2a

pT2b

pT2c

cT2a

cT2b

cT2c

Screening Bloodwork
Date of Tests: Date: _____/_____/_____
Were all tests performed on the same day?
Creatinine

Yes

No

__________ µmol/L

eGFR __________ ml/min/1.73m2 (must be > 60)
Urea __________ mmol/L
Sickle Cell Screen

Positive

Negative

Date Post-Void Ultrasound Performed: _____/_____/_____
Residual Bladder Volume: _________ mL (must be <150 cc)
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Patient Initials: ___ ___ ___ Study #: IGPC2-0 __ __

Protocol IGPC-2

Multi-modality Prostate Cancer Image Guided Interventions
CASE REPORT FORM

Pre-Operative Imaging Panel
Date of Scans
YYYY-MM-DD
Imaging Day 1

Dynamic CT/ 18F-FCH PET

_____/_____/_____

Optional PET/MRI or □N/A

_____/_____/_____

MRI (T1, T2, DWI, DCE, MRS)

_____/_____/_____

3D TRUS

_____/_____/_____

Imaging Day 2

Optional Na MRI

or □N/A

_____/_____/_____

Was entire imaging panel completed?
Yes
No
If No, state reason: _________________________________________________
________________________________________________________________
Has all imaging been completed within a 2 week period?
Yes
No
If No, state reason: _________________________________________________
________________________________________________________________
Has all imaging been completed within 6 weeks of RRP/ Biopsy?
Yes
No
If No, state reason: _________________________________________________
________________________________________________________________

PROCEDURE
Cohort 1: Radical Prostatectomy
Date _____/_____/_____ Time: _______ Location: _______ Surgeon: _________
Type of Surgery:

Open

Robotic Assisted Laparoscopic

Please check all that are applicable:
Nerve Sparing If yes, specify
Non-nerve Sparing
Sural nerve graft
Pelvic lymph node dissection performed?
Yes
No
Cohort 2: Prostate Biopsy

Unilateral R or L or

Bilateral

Date _____/_____/_____ Time: ______ Location: ______ Radiologist: _________
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Patient Initials: ___ ___ ___ Study #: IGPC2-0 __ __

Protocol IGPC-2

Multi-modality Prostate Cancer Image Guided Interventions
CASE REPORT FORM

Concomitant Medications / Treatments
Record all medications/ supplements/ treatments taken within 2 weeks of study start
and up to the day before Prostatectomy/ Prostate Biopsy.
Medication/
Supplement

Dose

Unit

Route

Freq.

CRA Completing CRF: ______________________________

Start
Date

Stop
Date

Date Completed: _____/_____/_____
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Patient Initials: ___ ___ ___ Study #: IGPC2-0 __ __

Protocol IGPC-2

Multi-modality Prostate Cancer Image Guided Interventions
CASE REPORT FORM

18F-FCH PET/CT Scan
Date of 18F-FCH PET/CT Scan: _____/_______/_____
Time of 18F-FCH Injection: ____:____
Vital Sign Assessments Throughout 18F-FCH PET/CT Scan
Heart Rate
Oxygen
Time
(bpm)
Saturation (%)
Baseline (prior to 18FFCH injection)

Blood Pressure
(mmhg)

Post PET Scan
Were venous samples collected?
Yes
Not Done
If not done, reason: ___________________________________________________
Venous Sampling during 18F-FCH PET of Pelvis
Sample #
Sampling
Check if
Time
Obtained
1-18FCH Injection
0 sec
2

20 sec

3
4
5

40 sec
60 sec
2 min

6
7

3 min
4 min

8
9
10

6 min
8 min
12 min

11

16 min

12
13

20 min
24 min

Did any adverse events occur during PET/CT scanning?
If yes, record in AE log.

Yes

No
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Protocol IGPC-2

Patient Initials: ___ ___ ___ Study #: IGPC2-0 __ __

Multi-modality Prostate Cancer Image Guided Interventions
CASE REPORT FORM

Optional PET/MRI Scan
Consented to Optional PET/MRI?

Yes

No

If Yes, Date of Optional PET/MRI Scan: _____/_______/_____
Did any adverse events occur during PET/MRI scanning?
If yes, record in AE log.

Yes

No

Optional Na MRI Scan
Consented to Optional Na MRI?

Yes

No

If Yes, Date of Optional Na MRI Scan: _____/_______/_____
Did any adverse events occur during Na MRI scanning?
If yes, record in AE log.

Yes

No

MRI/MRS Scan
Date of MRI Scan: _____/_______/_____
Did any adverse events occur during MRI scanning?
If yes, record in AE log.

Yes

No

Was a 3D TRUS performed following the MRI?

Yes

No

If no, reason: ______________________________________________________
_________________________________________________________________
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Patient Initials: ___ ___ ___ Study #: IGPC2-0 __ __

Protocol IGPC-2

Multi-modality Prostate Cancer Image Guided Interventions
CASE REPORT FORM

Adverse Events
*AE reporting is restricted to the study period prior to Radical Prostatectomy or
Biopsy (i.e. during imaging panel acquisition) as the Radical Prostatectomy and
Biopsy are not considered part of the study intervention.
Were there any adverse events?
Event

Causality
1 Unrelated
2 Unlikely
3 Possible
4 Probable
5 Definite

Start Date

No

Yes, complete below.

Stop Date

Severity Grade
1 Mild
2 Moderate
3 Severe
4 Life-threatening or disabling
5 Death

SAE
Y/N

Action Taken

Action Taken
1 No action taken
2 Medication taken
3 Imaging delayed/ stop prematurely
4 Withdrawn from study
88 Other- specify

CRF Completed By: _____________________

Date: ________________
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Appendix E – Curriculum Vitae
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